Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

被引：0
|
作者：
Voigt, Andrew P. [1 ]
Brodersen, Lisa Eidenschink [1 ]
Gerbing, Robert B. [2 ]
Menssen, Andrew J. [1 ]
Hirsch, Betsy A. [2 ,3 ]
Raimondi, Susana C. [2 ,4 ]
Gamis, Alan S. [2 ,5 ]
Alonzo, Todd A. [2 ,6 ]
Meshinchi, Soheil [2 ,7 ]
Loken, Michael R. [1 ]
机构：
[1] Hematologics Inc, Seattle, WA USA
[2] Childrens Oncol Grp, Monrovia, CA USA
[3] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA
[4] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
[5] Childrens Mercy Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Kansas City, MO USA
[6] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[7] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531
    Voigt, Andrew P.
    Brodersen, Lisa Eidenschink
    Alonzo, Todd A.
    Gerbing, Robert B.
    Menssen, Andrew J.
    Wilson, Elisabeth R.
    Kahwash, Samir
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Gamis, Alan S.
    Meshinchi, Soheil
    Wells, Denise A.
    Loken, Michael R.
    HAEMATOLOGICA, 2017, 102 (12) : 2058 - 2068
  • [2] Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531
    Pardo, Laura
    Brodersen, Lisa Eidenschink
    Lamba, Jatinder K.
    Alonzo, Todd A.
    Wang, Yi-Cheng
    Paine, Dana
    Gamis, Alan S.
    Kolb, E. Anders
    Pollard, Jessica A.
    Cooper, Todd M.
    Aplenc, Richard
    Meshinchi, Soheil
    Loken, Michael R.
    BLOOD, 2018, 132
  • [3] Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group
    Sung, Lillian
    Gerbing, Robert
    Alonzo, Todd A.
    Wang, Yi-Cheng
    Orgel, Etan
    Gamis, Alan S.
    Aplenc, Richard
    BLOOD, 2016, 128 (22)
  • [4] A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531
    Brodersen, Lisa Eidenschink
    Alonzo, Todd A.
    Menssen, Andrew J.
    Gerbing, Robert B.
    Pardo, Laura
    Voigt, Andrew P.
    Kahwash, Samir B.
    Hirsch, Betsy A.
    Raimondi, Susana C.
    Gamis, Alan S.
    Meshinchi, Soheil
    Loken, Michael R.
    BLOOD, 2015, 126 (23)
  • [5] ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial
    Rafiee, Roya
    Chauhan, Lata
    Alonzo, Todd A.
    Wang, Yi-Cheng
    Elmasry, Ahlam
    Loken, Michael R.
    Pollard, Jessica
    Aplenc, Richard
    Raimondi, Susana
    Hirsch, Betsy A.
    Bernstein, Irwin D.
    Gamis, Alan S.
    Meshinchi, Soheil
    Lamba, Jatinder K.
    BLOOD CANCER JOURNAL, 2019, 9
  • [6] ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
    Roya Rafiee
    Lata Chauhan
    Todd A. Alonzo
    Yi-Cheng Wang
    Ahlam Elmasry
    Michael R. Loken
    Jessica Pollard
    Richard Aplenc
    Susana Raimondi
    Betsy A. Hirsch
    Irwin D. Bernstein
    Alan S. Gamis
    Soheil Meshinchi
    Jatinder K. Lamba
    Blood Cancer Journal, 9
  • [7] Outcomes Based on CNS Disease Status in Pediatric Acute Myeloid Leukemia and the Role of Peripheral Blood Contamination in Diagnostic Lumbar Punctures; A Report from the Children's Oncology Group Studies AAML0531 and AAML1031
    Kutny, Matthew A.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Wang, Yi-Cheng
    Aplenc, Richard
    Gamis, Alan S.
    Feusner, James
    Woods, William G.
    Meshinchi, Soheil
    Johnston, Donna
    BLOOD, 2017, 130
  • [8] Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) - Combined Results from the Children's Oncology Group (COG) Trials, AAML03P1 and AAML0531
    Guest, Erin M.
    Aplenc, Richard
    Sung, Lillian
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Wang, Yi-Cheng
    Kahwash, Samir B.
    Heerema-McKenney, Amy
    Meshinchi, Soheil
    Gamis, Alan S.
    BLOOD, 2014, 124 (21)
  • [9] Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children's Oncology Group.
    Aplenc, Richard
    Fisher, Brian
    Li, Yimei
    Alonzo, Todd Allen
    Gerbing, Robert B.
    Hall, Matt
    Arnold, Staci D.
    Huang, Yuan-Shung
    Seif, Alix Eden
    Bagatell, Rochelle
    Sung, Lillian
    Adamson, Peter C.
    Gamis, Alan S.
    Keren, Ron
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group
    Getz, Kelly D.
    Li, Yimei
    Alonzo, Todd A.
    Hall, Matthew
    Gerbing, Robert B.
    Sung, Lillian
    Huang, Yuan-Shung
    Arnold, Staci
    Seif, Alix E.
    Miller, Tamara P.
    Bagatell, Rochelle
    Fisher, Brian T.
    Adamson, Peter C.
    Gamis, Alan
    Keren, Ron
    Aplenc, Richard
    PEDIATRIC BLOOD & CANCER, 2015, 62 (10) : 1775 - 1781
12345